Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin C Earp

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|November 26, 2013
Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactionsAndrew T Chow, Justin C Earp, Manish Gupta, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2008
Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis ratsJustin C Earp, Debra C Dubois, Diana S Molano, et al.
Journal of Clinical Pharmacology|November 9, 2023
Model-Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory PerspectiveXiaolei Pan, Li Wang, Jiang Liu, et al.
Journal of Clinical Pharmacology|May 18, 2017
The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation EvaluationDiane D Wang, Yanke Yu, Nastya Kassir, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Whole Body PBPK Modeling of Remdesivir and Its Metabolites to Aid in Estimating Active Metabolite Exposure in the Lung and Liver in Patients With Organ DysfunctionJianghong Fan, Yuching Yang, Manuela Grimstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 13, 2022
Reply to White et alEliford Kitabi, Timothy J Bensman, Justin C Earp, et al.
The AAPS Journal|June 25, 2013
Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshopJane R Kenny, Maggie M Liu, Andrew T Chow, et al.
Clinical Pharmacology and Therapeutics|November 22, 2021
Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 PandemicYe Xiong, Jianghong Fan, Eliford Kitabi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 19, 2021
Effect of Body Weight and Age on the Pharmacokinetics of Dihydroartemisinin: Food and Drug Administration Basis for Dose Determination of Artesunate for Injection in Pediatric Patients With Severe MalariaEliford Kitabi, Timothy J Bensman, Justin C Earp, et al.
Cancer Immunology, Immunotherapy : CII|August 5, 2008
Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodiesAllison S Drake, Michael T Brady, Xin Hui Wang, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|November 26, 2013
Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactionsAndrew T Chow, Justin C Earp, Manish Gupta, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2008
Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis ratsJustin C Earp, Debra C Dubois, Diana S Molano, et al.
Journal of Clinical Pharmacology|November 9, 2023
Model-Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory PerspectiveXiaolei Pan, Li Wang, Jiang Liu, et al.
Journal of Clinical Pharmacology|May 18, 2017
The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation EvaluationDiane D Wang, Yanke Yu, Nastya Kassir, et al.
Clinical Pharmacology and Therapeutics|October 16, 2021
Whole Body PBPK Modeling of Remdesivir and Its Metabolites to Aid in Estimating Active Metabolite Exposure in the Lung and Liver in Patients With Organ DysfunctionJianghong Fan, Yuching Yang, Manuela Grimstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 13, 2022
Reply to White et alEliford Kitabi, Timothy J Bensman, Justin C Earp, et al.
The AAPS Journal|June 25, 2013
Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshopJane R Kenny, Maggie M Liu, Andrew T Chow, et al.
Clinical Pharmacology and Therapeutics|November 22, 2021
Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 PandemicYe Xiong, Jianghong Fan, Eliford Kitabi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 19, 2021
Effect of Body Weight and Age on the Pharmacokinetics of Dihydroartemisinin: Food and Drug Administration Basis for Dose Determination of Artesunate for Injection in Pediatric Patients With Severe MalariaEliford Kitabi, Timothy J Bensman, Justin C Earp, et al.
Cancer Immunology, Immunotherapy : CII|August 5, 2008
Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodiesAllison S Drake, Michael T Brady, Xin Hui Wang, et al.
Pageof 3